Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women

Galis, 2002, Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly, Circ Res, 90, 251, 10.1161/res.90.3.251 Galis, 1994, Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques, J Clin Invest, 94, 2493, 10.1172/JCI117619 Blankenberg, 2003, Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease, Circulation, 107, 1579, 10.1161/01.CIR.0000058700.41738.12 Wu, 2005, Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease, Eur J Clin Invest, 35, 537, 10.1111/j.1365-2362.2005.01548.x Cavusoglu, 2006, Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction, Am Heart J, 151, 1101, 10.1016/j.ahj.2006.02.029 Eldrup, 2006, Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis, Circulation, 114, 1847, 10.1161/CIRCULATIONAHA.105.593483 Welsh, 2008, Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men, QJM, 101, 785, 10.1093/qjmed/hcn088 Ye, 2006, Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome, Cardiovasc Res, 69, 636, 10.1016/j.cardiores.2005.07.015 Yasmin, 2006, Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals, Arterioscler Thromb Vasc Biol, 26, 1799, 10.1161/01.ATV.0000227717.46157.32 Hlatky, 2007, Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease, Am Heart J, 154, 1043, 10.1016/j.ahj.2007.06.042 Kaplan, 2008, Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke, Atherosclerosis, 201, 130, 10.1016/j.atherosclerosis.2008.01.003 Walker, 2004, The British Regional Heart Study 1975–2004, Int J Epidemiol, 33, 1185, 10.1093/ije/dyh295 Lawlor, 2003, Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study, J Epidemiol Community Health, 57, 134, 10.1136/jech.57.2.134 Wannamethee, 2002, Physical activity and hemostatic and inflammatory variables in elderly men, Circulation, 105, 1785, 10.1161/hc1502.107117 Danesh, 2008, Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review, PLoS Med, 5, e78, 10.1371/journal.pmed.0050078 Emberson, 2004, Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study, Eur J Cardiovasc Prev Rehabil, 11, 125, 10.1097/01.hjr.0000114967.39211.e5 World Health Organization Expert Committee. Hypertension and coronary heart disease: classification and criteria for epidemiological studies. Geneva: World Health Organization; 1959. Report no.: 168. Rosner, 1992, Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error, Am J Epidemiol, 136, 1400, 10.1093/oxfordjournals.aje.a116453 Sundstrom, 2004, Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study, Circulation, 109, 2850, 10.1161/01.CIR.0000129318.79570.84 Garvin, 2008, Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population, PLoS ONE, 3, e1774, 10.1371/journal.pone.0001774 Thomas, 2002, Non-attendance at re-examination 20 years after screening in the British Regional Heart Study, J Public Health Med, 24, 285, 10.1093/pubmed/24.4.285 Gerlach, 2007, Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma, Clin Biochem, 40, 119, 10.1016/j.clinbiochem.2006.10.007 Thrailkill, 2006, Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens, Clin Chem Lab Med, 44, 503, 10.1515/CCLM.2006.090 Wu, 2007, Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution, Clin Cancer Res, 13, 2054, 10.1158/1078-0432.CCR-06-2299